Skip to main content
Erschienen in: AIDS and Behavior 3/2018

21.02.2017 | Original Paper

Acceptability of Early Antiretroviral Therapy Among South African Women

verfasst von: Nigel Garrett, Emily Norman, Kerry Leask, Nivashnee Naicker, Villeshni Asari, Nelisile Majola, Quarraisha Abdool Karim, Salim S. Abdool Karim

Erschienen in: AIDS and Behavior | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

WHO guidelines recommend immediate initiation of antiretroviral therapy (ART) for all individuals at HIV diagnosis regardless of CD4 count, but concerns remain about potential low uptake or poor adherence among healthy patients with high CD4 counts, especially in resource-limited settings. This study assessed the acceptability of earlier treatment among HIV-positive South African women, median age at enrollment 25 (IQR 22–30), in a 10 year prospective cohort study by (i) describing temporal CD4 count trends at initiation in relation to WHO guidance, (ii) virological suppression rates post-ART initiation at different CD4 count thresholds, and (iii) administration of a standardized questionnaire. 158/232 (68.1%) participants initiated ART between 2006 and 2015. Mean CD4 count at initiation was 217 cells/µl (range 135-372) before 2010, and increased to 531 cells/µl (range 272–1095) by 2015 (p < 0.001). Median viral load at ART initiation decreased over this period from 5.2 (IQR 4.6–5.6) to 4.1 (IQR 3.4–4.6) log copies/ml (p = 0.004). Virological suppression rates at 3, 6, 12 and 18 months were consistently above 85% with no statistically significant differences for participants starting ART at different CD4 count thresholds. A questionnaire assessing uptake of early ART amongst ART-naïve women, median age 28 (IQR 24–33), revealed that 40/51 (78.4%) were willing to start ART at CD4 ≥500. Of those unwilling, 6/11 (54.5%) started ART within 6 months of questionnaire administration. Temporal increases in CD4 counts, comparable virological suppression rates, and positive patient perceptions confirm high acceptability of earlier ART initiation for the majority of patients.
Literatur
2.
Zurück zum Zitat Doherty M, Ford N, Vitoria M, Weiler G, Hirnschall G. The 2013 WHO guidelines for antiretroviral therapy: evidence-based recommendations to face new epidemic realities. Curr Opin HIV AIDS. 2013;8(6):528–34.CrossRefPubMed Doherty M, Ford N, Vitoria M, Weiler G, Hirnschall G. The 2013 WHO guidelines for antiretroviral therapy: evidence-based recommendations to face new epidemic realities. Curr Opin HIV AIDS. 2013;8(6):528–34.CrossRefPubMed
4.
Zurück zum Zitat Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA. 2001;286(20):2568–77.CrossRefPubMed Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA. 2001;286(20):2568–77.CrossRefPubMed
5.
Zurück zum Zitat Moore RD, Keruly JC. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis. 2007;44(3):441–6.CrossRefPubMed Moore RD, Keruly JC. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis. 2007;44(3):441–6.CrossRefPubMed
6.
7.
Zurück zum Zitat Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet. 2010;375(9731):2092–8.CrossRefPubMedPubMedCentral Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet. 2010;375(9731):2092–8.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Baker JV, Peng G, Rapkin J, et al. CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS. 2008;22(7):841–8.CrossRefPubMedPubMedCentral Baker JV, Peng G, Rapkin J, et al. CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS. 2008;22(7):841–8.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795–807.CrossRef INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795–807.CrossRef
10.
Zurück zum Zitat Temprano, ANRS 12136 Study Group, Danel C, Moh R, Gabillard D, et al. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;373(9):808–22.CrossRef Temprano, ANRS 12136 Study Group, Danel C, Moh R, Gabillard D, et al. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;373(9):808–22.CrossRef
11.
Zurück zum Zitat Nachega JB, Parienti JJ, Uthman OA, et al. Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: a meta-analysis of randomized controlled trials. Clin Infect Dis. 2014;58(9):1297–307.CrossRefPubMedPubMedCentral Nachega JB, Parienti JJ, Uthman OA, et al. Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: a meta-analysis of randomized controlled trials. Clin Infect Dis. 2014;58(9):1297–307.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Langebeek N, Sprenger HG, Gisolf EH, et al. A simplified combination antiretroviral therapy regimen enhances adherence, treatment satisfaction and quality of life: results of a randomized clinical trial. HIV Med. 2014;15(5):286–90.CrossRefPubMed Langebeek N, Sprenger HG, Gisolf EH, et al. A simplified combination antiretroviral therapy regimen enhances adherence, treatment satisfaction and quality of life: results of a randomized clinical trial. HIV Med. 2014;15(5):286–90.CrossRefPubMed
13.
Zurück zum Zitat Fox MP, Mazimba A, Seidenberg P, Crooks D, Sikateyo B, Rosen S. Barriers to initiation of antiretroviral treatment in rural and urban areas of Zambia: a cross-sectional study of cost, stigma, and perceptions about ART. J Int AIDS Soc. 2010;6(13):8.CrossRef Fox MP, Mazimba A, Seidenberg P, Crooks D, Sikateyo B, Rosen S. Barriers to initiation of antiretroviral treatment in rural and urban areas of Zambia: a cross-sectional study of cost, stigma, and perceptions about ART. J Int AIDS Soc. 2010;6(13):8.CrossRef
14.
Zurück zum Zitat Zhang Q, Tang Z, Sun H, et al. Acceptability of early anti-retroviral therapy among HIV-infected people in Anhui province in China. AIDS Care. 2015;27(5):669–74.CrossRefPubMed Zhang Q, Tang Z, Sun H, et al. Acceptability of early anti-retroviral therapy among HIV-infected people in Anhui province in China. AIDS Care. 2015;27(5):669–74.CrossRefPubMed
15.
Zurück zum Zitat van Loggerenberg F, Mlisana K, Williamson C, et al. Establishing a cohort at high risk of HIV infection in South Africa: challenges and experiences of the CAPRISA 002 acute infection study. PLoS ONE. 2008;3(4):e1954.CrossRefPubMedPubMedCentral van Loggerenberg F, Mlisana K, Williamson C, et al. Establishing a cohort at high risk of HIV infection in South Africa: challenges and experiences of the CAPRISA 002 acute infection study. PLoS ONE. 2008;3(4):e1954.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168–74.CrossRefPubMedPubMedCentral Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168–74.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Mlisana K, Werner L, Garrett NJ, et al. Rapid disease progression in HIV-1 subtype C-infected South African women. Clin Infect Dis. 2014;59(9):1322–31.CrossRefPubMedPubMedCentral Mlisana K, Werner L, Garrett NJ, et al. Rapid disease progression in HIV-1 subtype C-infected South African women. Clin Infect Dis. 2014;59(9):1322–31.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Christopoulos KA, Olender S, Lopez AM, et al. Retained in HIV care but not on antiretroviral treatment: a qualitative patient-provider dyadic study. PLoS Med. 2015;12(8):e1001863.CrossRefPubMedPubMedCentral Christopoulos KA, Olender S, Lopez AM, et al. Retained in HIV care but not on antiretroviral treatment: a qualitative patient-provider dyadic study. PLoS Med. 2015;12(8):e1001863.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Katz IT, Dietrich J, Tshabalala G, Essien T, Rough K, Wright AA. Understanding treatment refusal among adults presenting for HIV-testing in Soweto, South Africa: a qualitative study. AIDS Behav. 2015;19(4):704–14.CrossRefPubMedPubMedCentral Katz IT, Dietrich J, Tshabalala G, Essien T, Rough K, Wright AA. Understanding treatment refusal among adults presenting for HIV-testing in Soweto, South Africa: a qualitative study. AIDS Behav. 2015;19(4):704–14.CrossRefPubMedPubMedCentral
Metadaten
Titel
Acceptability of Early Antiretroviral Therapy Among South African Women
verfasst von
Nigel Garrett
Emily Norman
Kerry Leask
Nivashnee Naicker
Villeshni Asari
Nelisile Majola
Quarraisha Abdool Karim
Salim S. Abdool Karim
Publikationsdatum
21.02.2017
Verlag
Springer US
Erschienen in
AIDS and Behavior / Ausgabe 3/2018
Print ISSN: 1090-7165
Elektronische ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-017-1729-2

Weitere Artikel der Ausgabe 3/2018

AIDS and Behavior 3/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.